Theravance Biopharma Inc (TBPH) Given Consensus Recommendation of “Hold” by Brokerages

Theravance Biopharma Inc (NASDAQ:TBPH) has received a consensus recommendation of “Hold” from the seven analysts that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and four have issued a buy recommendation on the company. The average 12 month price target among brokers that have covered the stock in the last year is $44.33.

Several research firms have recently issued reports on TBPH. Cantor Fitzgerald reaffirmed a “buy” rating and set a $55.00 price objective on shares of Theravance Biopharma in a research report on Monday, October 22nd. BidaskClub cut Theravance Biopharma from a “hold” rating to a “sell” rating in a research report on Thursday, July 26th. ValuEngine raised Theravance Biopharma from a “hold” rating to a “buy” rating in a research report on Thursday, August 9th. Finally, Piper Jaffray Companies reaffirmed an “overweight” rating and set a $55.00 price objective on shares of Theravance Biopharma in a research report on Wednesday, August 1st.

Shares of NASDAQ TBPH opened at $25.81 on Friday. The company has a current ratio of 4.14, a quick ratio of 3.95 and a debt-to-equity ratio of 6.52. Theravance Biopharma has a 1-year low of $21.27 and a 1-year high of $35.48. The stock has a market cap of $1.30 billion, a price-to-earnings ratio of -4.74 and a beta of 2.09.

Theravance Biopharma (NASDAQ:TBPH) last issued its quarterly earnings results on Tuesday, November 6th. The biopharmaceutical company reported ($1.10) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.18) by $0.08. Theravance Biopharma had a negative return on equity of 355.48% and a negative net margin of 513.41%. The company had revenue of $12.84 million for the quarter, compared to the consensus estimate of $10.55 million. On average, research analysts expect that Theravance Biopharma will post -4.26 earnings per share for the current fiscal year.

In other news, EVP Bradford J. Shafer sold 7,119 shares of the company’s stock in a transaction dated Monday, August 27th. The stock was sold at an average price of $27.71, for a total transaction of $197,267.49. Following the completion of the transaction, the executive vice president now directly owns 84,000 shares of the company’s stock, valued at approximately $2,327,640. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, SVP Philip D. Worboys sold 6,393 shares of the company’s stock in a transaction dated Wednesday, September 12th. The stock was sold at an average price of $28.50, for a total value of $182,200.50. Following the transaction, the senior vice president now directly owns 166,753 shares of the company’s stock, valued at $4,752,460.50. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 57,255 shares of company stock valued at $1,551,343. Insiders own 6.10% of the company’s stock.

Several large investors have recently added to or reduced their stakes in the company. UBS Group AG boosted its position in shares of Theravance Biopharma by 88.4% in the 1st quarter. UBS Group AG now owns 4,511 shares of the biopharmaceutical company’s stock valued at $109,000 after purchasing an additional 2,117 shares during the period. Xact Kapitalforvaltning AB acquired a new stake in shares of Theravance Biopharma in the 1st quarter valued at about $202,000. Royal Bank of Canada boosted its position in shares of Theravance Biopharma by 22.3% in the 1st quarter. Royal Bank of Canada now owns 16,664 shares of the biopharmaceutical company’s stock valued at $404,000 after purchasing an additional 3,042 shares during the period. State Board of Administration of Florida Retirement System boosted its position in shares of Theravance Biopharma by 12.2% in the 2nd quarter. State Board of Administration of Florida Retirement System now owns 28,578 shares of the biopharmaceutical company’s stock valued at $648,000 after purchasing an additional 3,100 shares during the period. Finally, Engineers Gate Manager LP acquired a new stake in shares of Theravance Biopharma in the 3rd quarter valued at about $662,000. 84.74% of the stock is owned by institutional investors and hedge funds.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc, a diversified biopharmaceutical company, discovers, develops, and commercializes human therapeutics. The company offers VIBATIV (telavancin), a bactericidal, once-daily injectable antibiotic to treat patients with infections due to Staphylococcus aureus and other Gram-positive bacteria.

Further Reading: What is a Call Option?

Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply